Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment

ROCHESTER, Minn. ? A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. The results are published today in the New England Journal of Medicine. Autosomal dominant [...]
Source: Mayo Clinic Minnesota News - Category: Hospital Management Source Type: news